Jun 29, 2015, 08:30 ET
HAMILTON, Bermuda, June 29, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the acceptance of two presentations at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015.
The data will be presented via oral and poster presentations as follows:
Efficacy of RVT-101 in Mild-Moderate Alzheimer's Disease: Completer Analysis (Oral Presentation):
The Efficacy of RVT-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study will be presented during the Developing Topics Session: Clinical Trial Results on Wednesday, July 22, 2015, 2:00-3:30 p.m. (Hall E; # DT-01-04).
Efficacy of RVT-101 in Mild-Moderate Alzheimer's Disease: Responder Analysis (Poster Presentation):
RVT-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis will be presented during the Therapeutics: Clinical poster session on Wednesday July 22, 2015, 9:30 a.m. - 4:15 p.m. (Exhibit Hall E; # P4-302).
RVT-101 is an orally administered, potent antagonist of the 5-HT6 serotonin receptor. Antagonism of the 5-HT6 receptor is a novel mechanism of action that promotes the release of acetylcholine, glutamate and other neurotransmitters thought to improve cognition and function in patients suffering from Alzheimer's disease and other forms of dementia. RVT-101 has been studied in 13 clinical trials involving over 1,250 human subjects with a favorable safety and tolerability profile. Axovant intends to commence a confirmatory phase 3 clinical study testing RVT-101 on a background of donepezil therapy in mild-to-moderate Alzheimer's disease patients in the fourth quarter of 2015.
RVT-101 is an investigational new drug candidate and is not approved for any indication in any markets.
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia.
Forward Looking Statements
This press release contains forward-looking statements, including statements regarding Axovant's participation in the Alzheimer's Association International Conference 2015 (AAIC), as well as the subject matter of Axovant's presentations at the conference, including the plans, strategies, and objectives of management for future operations, and clinical data. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidate RVT-101; and increased regulatory requirements; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see Axovant's Prospectus filed with the Securities and Exchange Commission on June 11, 2015. These forward-looking statements speak only as of the date hereof. Axovant Sciences disclaims any obligation to update these forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20150629/226455LOGO
SOURCE Axovant Sciences Ltd.
Share this article